Good find. If Shattuck is successful I expect Takeda will buy them up as they did with ARIAD($5.2 Billion). And as Shattuck's technology is at least partly exclusively licensed from Heat...I would expect they will also be watching Heat. Takeda is a very large international Japanese pharma...which was relatively weak in oncology...hence their purchase of ARIAD, collaboration with Shattuck and IMO potential interest in Heat! Along with the 5 big pharmas who have checkpoint inhibitors who need help to improve efficacy and safety...we can add Takeda who are clearly seeking to make up their oncology deficit.
More coverage on the Shattuck Lab/Takeda collaboration. According to the bizjoural article Heat will benefit from milestone payments and royalties. And Takeda is obviously aware of Heat/Pelican technology. Takeda is very aggressive in the oncology arena...trying to make up ground! Will more be heard from Takeda? http://www.fiercebiotech.com/biotech/takeda-taps-texas-start-up-for-double-whammy-cancer-immunotherapies
News 
Market Data 
Discover 
